GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (OTCPK:SHPGF) » Definitions » Beneish M-Score

Shire (SHPGF) Beneish M-Score : 0.00 (As of Apr. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Shire Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Shire's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Shire was 0.00. The lowest was 0.00. And the median was 0.00.


Shire Beneish M-Score Historical Data

The historical data trend for Shire's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Beneish M-Score Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.69 -2.44 -2.45 -1.41 -2.35

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 -2.35 -2.46 -2.44 -2.24

Competitive Comparison of Shire's Beneish M-Score

For the Biotechnology subindustry, Shire's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shire's Beneish M-Score falls into.



Shire Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shire for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0658+0.528 * 0.9913+0.404 * 0.9774+0.892 * 1.0594+0.115 * 0.9266
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8909+4.679 * 0.007553-0.327 * 0.8164
=-2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep18) TTM:Last Year (Sep17) TTM:
Total Receivables was $3,207 Mil.
Revenue was 3871.7 + 3919.5 + 3765.7 + 4144.9 = $15,702 Mil.
Gross Profit was 2714.1 + 2811.2 + 2633.3 + 2881.4 = $11,040 Mil.
Total Current Assets was $7,799 Mil.
Total Assets was $63,766 Mil.
Property, Plant and Equipment(Net PPE) was $6,453 Mil.
Depreciation, Depletion and Amortization(DDA) was $2,428 Mil.
Selling, General, & Admin. Expense(SGA) was $3,433 Mil.
Total Current Liabilities was $8,512 Mil.
Long-Term Debt & Capital Lease Obligation was $11,098 Mil.
Net Income was 537.2 + 615.5 + 550.6 + 3105.4 = $4,809 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 857.6 + 939.6 + 1010.3 + 1519.6 = $4,327 Mil.
Total Receivables was $2,841 Mil.
Revenue was 3697.6 + 3745.8 + 3572.3 + 3806.1 = $14,822 Mil.
Gross Profit was 2696.2 + 2636.9 + 2245.3 + 2752.5 = $10,331 Mil.
Total Current Assets was $7,292 Mil.
Total Assets was $67,477 Mil.
Property, Plant and Equipment(Net PPE) was $6,580 Mil.
Depreciation, Depletion and Amortization(DDA) was $2,233 Mil.
Selling, General, & Admin. Expense(SGA) was $3,637 Mil.
Total Current Liabilities was $7,461 Mil.
Long-Term Debt & Capital Lease Obligation was $17,956 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3207.4 / 15701.8) / (2840.7 / 14821.8)
=0.20427 / 0.191657
=1.0658

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10330.9 / 14821.8) / (11040 / 15701.8)
=0.697007 / 0.703104
=0.9913

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7799.3 + 6453) / 63765.9) / (1 - (7291.5 + 6579.5) / 67476.5)
=0.77649 / 0.794432
=0.9774

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=15701.8 / 14821.8
=1.0594

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2232.5 / (2232.5 + 6579.5)) / (2428.3 / (2428.3 + 6453))
=0.253348 / 0.273417
=0.9266

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3432.5 / 15701.8) / (3637.1 / 14821.8)
=0.218606 / 0.245389
=0.8909

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11098 + 8511.6) / 63765.9) / ((17956 + 7461.1) / 67476.5)
=0.307525 / 0.376681
=0.8164

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(4808.7 - 0 - 4327.1) / 63765.9
=0.007553

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shire has a M-score of -2.27 suggests that the company is unlikely to be a manipulator.


Shire (SHPGF) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Shire (SHPGF) Headlines

From GuruFocus

Takeda Closes In on Shire, But It's Not a Done Deal Yet

By John Engle John Engle 05-08-2018

4 Stocks John Paulson and Paul Tudor Jones Agree On

By Sydnee Gatewood Sydnee Gatewood 09-21-2018

Shire's Tug of War

By Maxwell Koobatian Maxwell Koobatian 04-23-2018